Institutions · Entity Annotation Prototype (beta)

32articles mentioning institutions

107institution mentions

1distinct institutions extracted

0%of mentions human-reviewed

Active filtersEntity: FDA ×

FDA

This institution is selected. Its supporting articles are shown below.

FDA32

Articles mentioning FDA

32 articles · page 3 of 3

372 Cell surface marker-based enrichment of CD4+ neoantigen-reactive tumor infiltrating lymphocytes from metastatic epithelial cancers

jitc · abstract · 2025-11-04 · 1 matching annotations

80.8%

National Cancer Institute FDA metastatic melanoma metastatic epithelial cancers Lifileucel IL-2

… This protocol (03-C-0277) was performed at the Surgery Branch, National Cancer Institute, and obtained ethics approval in compliance with the IRB in acc…

74 Automated co-detection of small RNAs, RNAs and proteins with Roche DISCOVERY™ ULTRA

jitc · abstract · 2025-11-04 · 1 matching annotations

90.1%

FDA FDA Roche DISCOVERY™ ULTRA System neurodegenerative/neuromuscular disorders rare diseases EMA

… and EMA, and many more are in clinical phase I-III trials. The FDA has issued recommendations to generate nonclinical biodistribut…

S146 Inflammation and obesity correlate in pulmonary hypertension but associate with diverging outcomes

thoraxjnl · abstract · 2025-11-02 · 1 matching annotations

82.2%

FDA ASPIRE Pulmonary Hypertension PH

… using clinical cut off values (n=10,301; UK-cohort, ASPIRE and FDA cohort). Associations were analysed with functional and mortali…

Neurofunctional phenotyping to investigate the role of the orexin system at the intersection of opioid use disorder and insomnia: a protocol for a randomised, placebo-controlled clinical trial of lemborexant in patients with insomnia receiving buprenorphine

bmjopen · abstract · 2025-10-28 · 1 matching annotations

77.9%

Virginia Commonwealth University Institutional Review Board FDA FDA lemborexant buprenorphine opioid use disorder insomnia BUP OUD Food and Drug Administration

…ognition.Ethics and dissemination The study was approved by the Virginia Commonwealth University Institutional Review Board in April 2025 (protocol number HM20031777). Data collection beg…

Qualitative study of oncologists’ perceptions on the US Food and Drug Administration approval status and clinical practice guidelines and their impact on local practice patterns in India

bmjonc · full text · 2025-10-22 · 1 matching annotations

77.4%

Tata Hospital National Comprehensive Cancer Network European Society for Medical Oncology Indian Council of Medical Research Indian Society of Medical and Pediatric Oncology ASCO ICMR American Society of Clinical Oncology NCG NCCN+4 more

…ls. (P8) Lack of institutional protocolsMost institutes, unlike Tata Hospital, don’t have their own protocols. (P7) Robustness and timely upd…

Clinical prediction models using machine learning in oncology: challenges and recommendations

bmjonc · full text · 2025-10-07 · 1 matching annotations

75.8%

SEER ClinicalTrials.gov FDA prostate cancer breast cancer gastric cancer venous thromboembolism melanoma oncology kidney+1 more

…odel for use in China but using training data from the USA (eg, SEER) needs careful consideration and justification.Class imbalance …

Gender bias in biomedical research

ejhpharm · abstract · 2025-10-07 · 1 matching annotations

90.5%

FDA adverse drug reactions

…e by Castellana and Chiappetta presents data collected from the FDA Adverse Event Reporting System (FAERS) illustrating a long-stan…

Is the FDA regulation of cardiology AI devices supporting cardiovascular innovation: a scoping review

heartjnl · abstract · 2025-08-20 · 1 matching annotations

79.7%

US Food and Drug Administration FDA

…patient care. This study presents a comprehensive evaluation of US Food and Drug Administration (FDA)-approved AI/ML devices in cardiology, analysing trends in…

Browse institutions

FDA

Articles mentioning FDA